Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Astria Therapeutics, Inc. (ATXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/12/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/12/2023 8-K Quarterly results
10/11/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
10/11/2023 8-K Quarterly results
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/24/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/11/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/31/2023 8-K Quarterly results
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 6.9% stake in Astria Therapeutics, Inc.
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 6.3% stake in Astria Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 8-K Quarterly results
01/10/2023 SC 13G FMR LLC reports a 12.8% stake in ASTRIA THERAPEUTICS INC
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Forward Looking Statements This presentation and various remarks we make during this presentation contain forward - looking statements of Astria Therapeutics, Inc . within the meaning of applicable securities laws and regulations, including statements with respect to : the Company’s projected cash runway and cash, cash equivalents and short - term investments as of 12 / 30 / 2022 ; expectations regarding the nature, timing and potential significance of the preliminary results from the Phase 1 a STAR - 0215 trial, the plans to add additional cohorts to the trial and the anticipated nature and timing of receipt of the data from such additional cohorts ; expectations regarding the timing of initiation, design and timing and nature of the anticipated proof of concept results from the planned P..."
12/22/2022 SC 13G Deep Track Capital, LP reports a 7.3% stake in Astria Therapeutics, Inc.
12/21/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/21/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/15/2022 8-K Quarterly results
12/15/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/15/2022 8-K Quarterly results
11/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/10/2022 8-K Quarterly results
11/10/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter re: Prospectus Supplement to Registration Statement on Form S-3"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy